Compare Arko Corp. (ARKO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Merck & Co., Inc. — how do they compare? Arko Corp. trades at $4.59 (market cap $493.06M), while Merck & Co., Inc. trades at $133.55 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 652.6× Arko Corp.'s market cap, and Arko Corp. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| ARKO | MRK | |
|---|---|---|
Market Cap | $493.06M | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $131.84 |
52-Week Low | $3.82 | $77.60 |
Enterprise Value | $2.67B | $368.53B |
Dividend Yield | 2.73% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.45, down 5.32% amid weak Q2 2026 earnings that missed estimates. The stock is in a bearish technical trend with key support at $4. Revenue has declined from $9.4B in 2023 to $7.6B in 2025, though net income margins remain thin at 0.19%. Recent news highlights pressure from softer retail demand and elevated fuel costs, despite management maintaining full-year EBITDA guidance.
The outlook is cautious with 100% hold ratings from analysts, reflecting concerns over margin compression and volatile consumer spending. Risks include high debt levels and competitive pressures, but the company's consistent dividend payments and positive operating cash flow offer some stability. Further price movement hinges on execution against guidance and macroeconomic conditions.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
